Who are ADH -1 and docetaxel's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adh-1-and-docetaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ADH -1 and docetaxel — Competitive Intelligence Brief

ADH -1 and docetaxel (ADH -1 and docetaxel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: angiostatic peptide and microtubule inhibitor. Area: Oncology.

phase 1 angiostatic peptide and microtubule inhibitor heparin sulfate proteoglycans and tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ADH -1 and docetaxel (ADH -1 and docetaxel) — Adherex Technologies, Inc.. ADH-1 is an angiostatic peptide that inhibits angiogenesis by binding to heparin sulfate proteoglycans on the surface of endothelial cells, while docetaxel is a microtubule inhibitor that blocks cell division.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ADH -1 and docetaxel TARGET	ADH -1 and docetaxel	Adherex Technologies, Inc.	phase 1	angiostatic peptide and microtubule inhibitor	heparin sulfate proteoglycans and tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (angiostatic peptide and microtubule inhibitor class)

Adherex Technologies, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ADH -1 and docetaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/adh-1-and-docetaxel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab